DarioHealth Corp.
07/05/2024 | Press release | Distributed by Public on 07/05/2024 14:07
Initial Registration Statement for Employee Benefit Plan Form S 8
As filed with the Securities and Exchange Commission on July 5, 2024
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
DARIOHEALTH CORP.
(Exact name of registrant as specified in its charter)
|
Delaware (State or other jurisdiction of incorporation or organization) |
45-2973162 (I.R.S. Employer Identification No.) |
322 W 57th St, #33B
New York, New York 10019
(Address of Principal Executive Offices)
DarioHealth Corp. 2020 Equity Incentive Plan
(Full title of the plan)
Mr. Erez Raphael
Chief Executive Officer
322 W 57th St, #33B
New York, New York 10019
Telephone: 972-4-770-6377
(Name, Address and Telephone Number of Agent For Service)
Copies to:
Oded Har-Even, Esq.
Ron Ben-Bassat, Esq.
Sullivan & Worcester LLP
1251 Avenue of the Americas
New York, NY 10020
Telephone: (212) 660-3000
Facsimile: (212) 660-3001
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act
| Large accelerated filer ¨ | Accelerated filer ¨ | Non-accelerated filer x | Smaller reporting company x | Emerging growth company ¨ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
Explanatory Note
On October 14, 2020, DarioHealth Corp. (the "Company") filed a Registration Statement on Form S-8 (File No. 333-249474) (the "Original Registration Statement") with the Securities and Exchange Commission (the "Commission") to register an aggregate of 900,000 shares of the Company's common stock, $0.0001 par value per share (the "Common Stock"), that may be issued pursuant to the Company's 2020 Equity Incentive Plan, as amended (the "2020 Plan").
On January 8, 2021, the Company filed a Registration Statement on Form S-8 (File No. 333-251968) (the "Second Registration Statement") with the Commission to register an additional 928,890 shares of Common Stock that may be issued pursuant to the 2020 Plan.
On June 8, 2021, the Company filed a Registration Statement on Form S-8 (File No. 333-256897) (the "Third Registration Statement") with the Commission to register an additional 700,000 shares of Common Stock that may be issued pursuant to the 2020 Plan.
On January 7, 2022, the Company filed a Registration Statement on Form S-8 (File No. 333-262056) (the "Fourth Registration Statement") with the Commission to register an additional 1,339,624 shares of Common Stock that may be issued pursuant to the 2020 Plan.
On January 6, 2023, the Company filed a Registration Statement on Form S-8 (File No. 333-269147) (the "Fifth Registration Statement") with the Commission to register an additional 1,994,346 shares of Common Stock that may be issued pursuant to the 2020 Plan.
On January 19, 2024, the Company filed a Registration Statement on Form S-8 (File No. 333-276617) (the "Sixth Registration Statement" and together with the Original Registration Statement, the Second Registration Statement, the Third Registration Statement, the Fourth Registration Statement and the Fifth Registration Statement, the "Prior Registration Statements") with the Commission to register an additional 2,493,764 shares of Common Stock that may be issued pursuant to the 2020 Plan.
Pursuant to the 2020 Plan, the number of shares of Common Stock of the Company made available under the 2020 Plan for each of the calendar years ending on December 31, 2022, December 31, 2023, December 31, 2024, and December 31, 2025 shall be increased by an additional number of shares of Common Stock equal to six percent (6%) of the number of shares of Common Stock issued and outstanding on a fully diluted basis (as defined in the 2020 Plan) on the immediately preceding December 31.
The Company is filing this registration statement to register an additional 3,000,000 shares of Common Stock that may be issued under the 2020 Plan. The Company's stockholders approved increasing the reservation of aforementioned additional shares under the 2020 Plan at the Company's 2024 Special Meeting of Stockholders on June 25, 2024.
Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference, except for Item 3 and Item 8 of Part II of the Prior Registration Statements, which are being updated by this registration statement.
PART I
INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS
The documents containing the information required in Part I of this registration statement have been or will be sent or given to participating employees as specified in Rule 428(b)(1) under the Securities Act of 1933, as amended (the "Securities Act") in accordance with the rules and regulations of the Commission. Such documents are not being filed with the Commission either as part of this registration statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents incorporated by reference into this registration statement pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 3.Incorporation of Documents by Reference.
The following documents, which have been filed by the Company with the Commission are incorporated by reference in and made a part of this registration statement, as of their respective dates:
| (1) | Our Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Commission on March 28, 2024; |
| (2) | Our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024, as filed with the Commission on May 15, 2024; |
| (3) | Our Current Reports on Form 8-K, as filed with the Commission on February 21, 2024 (with respect to the first two paragraphs, the fifth and sixth paragraphs, the ninth paragraph through the eighteenth paragraph and the section titled "Cautionary Note Regardig Forward-Looking Statements" in the press release attached as Exhibit 99.2 to the Current Report on Form 8-K and excluding Ex. 99.1 which was furnished with the Current Report on Form 8-K), March 1, 2024, April 5, 2024, April 19, 2024, April 22, 2024, June 5, 2024, June 25, 2024 and June 28, 2024; and |
All documents subsequently filed by us with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be part hereof from the date of filing of such documents.
Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement herein, or in any subsequently filed document which also is or is deemed to be incorporated by reference, modifies or supersedes such statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.
Item 8. Exhibits.
| * | filed herewith |
SIGNATURES
Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement on Form S-8 to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of New York, New York, on the 5th day of July, 2024.
| DARIOHEALTH CORP. | ||
| By: | /s/ Erez Raphael | |
| Name: Erez Raphael | ||
| Title: Chief Executive Officer |
POWER OF ATTORNEY AND SIGNATURES
We, the undersigned officers and directors of DarioHealth Corp., hereby severally constitute and appoint Erez Raphael and Zvi Ben David, and each of them individually, our true and lawful attorney to sign for us and in our names in the capacities indicated below any and all amendments or supplements, including any post-effective amendments, to this registration statement on Form S-8 and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney full power and authority to do and perform each and every act and thing requisite or necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming our signatures to said amendments to this registration statement signed by our said attorney and all else that said attorney may lawfully do and cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act, this registration statement on Form S-8 has been signed below by the following persons in the capacities and on the dates indicated.
| Person | Capacity | Date | ||
| /s/ Erez Raphael | Chief Executive Officer | July 5, 2024 | ||
| Erez Raphael | (Principal Executive Officer) | |||
| /s/ Zvi Ben David | Chief Financial Officer, Secretary and Treasurer | July 5, 2024 | ||
| Zvi Ben David | (Principal Financial and Accounting Officer) | |||
| /s/ Yoav Shaked | Chairman of the Board of Directors | July 5, 2024 | ||
| Yoav Shaked | ||||
| /s/ Hila Karah | Director | July 5, 2024 | ||
| Hila Karah | ||||
| /s/ Dennis Matheis | Director | July 5, 2024 | ||
| Dennis Matheis | ||||
| /s/ Dennis M. McGrath | Director | July 5, 2024 | ||
|
Dennis M. McGrath |
||||
| /s/ Adam K. Stern | Director | July 5, 2024 | ||
| Adam K. Stern | ||||
| /s/ Jon Kaplan | Director | July 5, 2024 | ||
| Jon Kaplan |